1. Home
  2. CODA vs SPRO Comparison

CODA vs SPRO Comparison

Compare CODA & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

N/A

Current Price

$14.56

Market Cap

155.4M

Sector

Industrials

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$2.54

Market Cap

124.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CODA
SPRO
Founded
1994
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.4M
124.5M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
CODA
SPRO
Price
$14.56
$2.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
265.8K
240.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
15.62
N/A
EPS
0.37
N/A
Revenue
$20,316,161.00
$47,977,000.00
Revenue This Year
$16.42
N/A
Revenue Next Year
$14.43
N/A
P/E Ratio
$45.76
N/A
Revenue Growth
4.98
N/A
52 Week Low
$5.76
$0.51
52 Week High
$17.28
$3.09

Technical Indicators

Market Signals
Indicator
CODA
SPRO
Relative Strength Index (RSI) 54.66 68.12
Support Level $7.25 $2.15
Resistance Level $14.89 $2.70
Average True Range (ATR) 1.04 0.09
MACD 0.10 0.03
Stochastic Oscillator 31.76 98.11

Price Performance

Historical Comparison
CODA
SPRO

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: